Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2002

01-11-2002

Breast Cancers Found by Screening: Earlier Detection, Lower Malignant Potential or Both?

Authors: Miranda F. Ernst, Jan A. Roukema, Jan-Willem W. Coebergh, Ocker J. Repelaer van Driel, Mike W.P.M. van Beek, Maurice J.C. van der Sangen, Adri C. Voogd

Published in: Breast Cancer Research and Treatment | Issue 1/2002

Login to get access
Metadata
Title
Breast Cancers Found by Screening: Earlier Detection, Lower Malignant Potential or Both?
Authors
Miranda F. Ernst
Jan A. Roukema
Jan-Willem W. Coebergh
Ocker J. Repelaer van Driel
Mike W.P.M. van Beek
Maurice J.C. van der Sangen
Adri C. Voogd
Publication date
01-11-2002
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2002
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1020213817562

Other articles of this Issue 1/2002

Breast Cancer Research and Treatment 1/2002 Go to the issue

OriginalPaper

Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database

OriginalPaper

Docetaxel Plus Vinorelbine as Salvage Chemotherapy in Advanced Breast Cancer: A Phase II Study

OriginalPaper

Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy

OriginalPaper

T1 Breast Cancer: Identification of Patients at Low Risk of Axillary Lymph Node Metastases

OriginalPaper

Cyclooxygenase Inhibitors Block Cell Growth, Increase Ceramide and Inhibit Cell Cycle

OriginalPaper

Predictors of Sensitivity of Clinical Breast Examination (CBE)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits